Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dianthus Therapeutics, Inc. - Common Stock
(NQ:
DNTH
)
28.75
-1.06 (-3.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dianthus Therapeutics, Inc. - Common Stock
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
August 08, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
June 28, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
June 12, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
May 09, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
May 08, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 11, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
February 26, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.